Pre-clinical models have shown that upregulation of the FcγRIIb at the tumour site prevented intra-tumoral Treg cell depletion carried out by anti-CD25 mAb, which limits its activity against established tumours (148). This evidence concerns the gene FCGR2B and neoplasm.